That's a poster child of a casualty of ZIRP. Hard to imagine an industry any longer duration and hungry for cheap risk.
I'm not sure about the thesis that this is primarily fallout from free money and suppressed interest rates though. That was really a '22 story, and even with long and variable lags, that element has been in play for a while now.
Oversupply of talent definitely sounds like a good argument though. I'll posit there has been some disruption by recent developments in the industry. Also, while metaverse and crypto startups may be passe, the AI scene has disgusting amounts of hype and money, and crypto ain't dead either, which brings me back to the earlier point that I do think some disruption is there to fill the gap in the narrative.
For people I talk, it is the end of ZIRP that caused it. ZIRP ended in April 2022.
Even as interest rates went up the VCs still had committed funds to distribute for a year to 18 months. Then the biotechs had runway for 1-2 years from that. Now that’s all gone, and they can’t raise their next series. In the meantime, C> plus synbio is recently having a lower win rate than hoped for.
That plus all the money that is there is all going to AI companies due to the shorter time to return / higher potential roic / hype.
